Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Dr Robert Watson has won one of three McElwain and President's Prizes from the Association of Cancer Physicians for his DPhil work undertaken with Professor Ben Fairfax.

The Association of Cancer Physicians (ACP) is the speciality organisation for medical oncology in the UK. The McElwain Awards were established by the friends and colleagues of the late Professor Tim McElwain to commemorate his extraordinary contribution to the development of Medical Oncology in the UK.  In addition, since 2020, the ACP also offers an additional President's Prize.  The Prizes are awarded annually to UK trainees in medical oncology who have performed high-quality research on either clinical or basic research related to cancer.

Dr Robert Watson is one of three prize-winners selected by the ACP for the McElwain and Presidents Prizes in 2023 for their outstanding applications. This award resulted from peer review of his DPhil work performed in the Fairfax Group. Robert focussed on transcriptomic and clonal changes to CD8+ T-cells following immune checkpoint blockade treatment in patients with metastatic melanoma and renal cell carcinoma. In particular, his work looked at T-cell repertoire changes in both the short-term and following a long-term response to PD-1 blockade. His results have been published in Science Immunology and Nature Medicine, with a further paper currently in pre-print, as well as oral presentations at the ESMO and IUIS congresses. Robert has remained in the Fairfax Group in the Department of Oncology, having been awarded a Clinical Lecturer position funded by the CRIS cancer foundation - this will allow him to continue to conduct post-doctoral research, alongside finishing his clinical training in medical oncology. 

Robert said: “It is humbling to be awarded the McElwain Prize for my DPhil work in Ben’s group, and I’m extremely proud to have national recognition for our research which aims to improve immunotherapy treatment for patients with advanced cancers.  None of it would have been possible without contributions from many others including talented colleagues in the Fairfax Group, core facilities at the MRC WIMM - particularly the Single Cell facility - staff and patients at OUH and supervision from Ben Fairfax and Mark Middleton."

Professor Ben Fairfax said: "I am so pleased that Rob has been awarded this prize - it reflects his hard work and great approach over a number of years and it is wonderful to see this being recognised."

Many congratulations to Dr Watson!

Similar stories

Prof Anna Schuh launches first private specialised haematology clinic and laboratory in sub-Saharan Africa.

SerenOx Africa aims to address diagnostic gaps for common blood disorders through a testing facility for key underserved patient populations in Tanzania. This facility will also aim to provide early cancer detection for high-risk patients.

Professor Eileen Parkes appointed to lead Oxford’s Experimental Cancer Medicine Centre

Eileen Parkes, Associate Professor in Innate Tumour Immunology in the Department of Oncology, will lead the expansion of the centre’s programmes in early drug development and biomarker research.

Machine Learning Predicts SETD2 Mutation Status with Unprecedented Accuracy using DNA methylation

In a pan-cancer analysis spanning 24 different cancer type, researchers shed light on the critical role of SETD2 in tumourigenesis.

Oxford to launch UK’s first trials unit dedicated to conducting precision prevention and early detection studies

Oxford researchers have been given a £1 million boost to support their strategy of developing cancer prevention treatments and early diagnostic tools for people at high risk of cancer.

Multi-cancer blood test shows real promise in NHS trial

An NHS trial of a new blood test for more than 50 types of cancer correctly revealed two out of every three cancers in more than 5,000 people who had visited their GP with suspected symptoms, in England or Wales. The test also correctly identified the original site of cancer in 85% of those cases.

The Howat Foundation to fund Chair in Clinical Oncology

Oxford Cancer announce the endowment of a Chair in Clinical Oncology, thanks to generous philanthropic support from The Howat Foundation